Limitations in Assessing Cardiovascular Risk of Febuxostat in Patients With Gout and Cardiovascular Morbidities: Comment on the Article by Choi et al
- 18 January 2019
- journal article
- letter
- Published by Wiley in Arthritis & Rheumatology
- Vol. 71 (6) , 1023-1024
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus AllopurinolCirculation, 2018
- New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety AlertArthritis & Rheumatology, 2018
- Cardiovascular Safety of Febuxostat or Allopurinol in Patients with GoutNew England Journal of Medicine, 2018